Literature DB >> 3298922

Adverse reactions with oral and parenteral gold preparations.

E C Tozman, N L Gottlieb.   

Abstract

Auranofin (triethylphosphine gold), an oral gold preparation, has recently been made available, and along with injectable gold preparations, is of therapeutic value for rheumatoid arthritis. Serious gold toxicity is uncommon, and drug-related deaths rare. Many potential adverse reactions are similar, including dermatitis, stomatitis, thrombocytopenia, leucopenia, and proteinuria, generally with increased incidence in the injectable gold-treated patients. Oral gold is associated with benign lower gastrointestinal side effects, including diarrhoea, loose stools and abdominal cramps that are often dose-related and resolve spontaneously. The incidence of severe reactions such as thrombocytopenia, aplastic anaemia and exfoliative dermatitis is lower with oral gold than injectable preparations, and contributes to a superior risk-benefit ratio. The treatment of gold toxicity depends on the type and extent of organ involvement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298922     DOI: 10.1007/BF03259863

Source DB:  PubMed          Journal:  Med Toxicol        ISSN: 0112-5966


  90 in total

1.  Increasing the effectiveness of gold therapy in rheumatoid arthritis.

Authors:  R T SMITH; W P PEAK; K M KRON; I F HERMANN; R A DELTORO; M GOLDMAN
Journal:  J Am Med Assoc       Date:  1958-07-05

2.  Treatment of two reactions due to gold; response of thrombopenic purpura and granulocytopenia to BAL therapy.

Authors:  L M LOCKIE; B M NORCROSS; C W GEORGE
Journal:  J Am Med Assoc       Date:  1947-03-15

3.  Gold nephropathy prototype of membranous glomerulonephritis.

Authors:  T Tönroth; B Skrifvars
Journal:  Am J Pathol       Date:  1974-06       Impact factor: 4.307

4.  Gold-associated thrombocytopenia. Report six cases.

Authors:  B Deren; R Masi; M Weksler; R L Nachman
Journal:  Arch Intern Med       Date:  1974-12

5.  Depression of bone marrow and thrombocytopenia associated with chrysotherapy.

Authors:  A Kay
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

6.  Gold nephropathy. A clinical and pathologic study.

Authors:  D S Silverberg; E G Kidd; T K Shnitka; R A Ulan
Journal:  Arthritis Rheum       Date:  1970 Nov-Dec

7.  Heme metabolism in the fetoplacental unit and neonatal livers during lactation: effect of gold sodium thiomalate.

Authors:  J L Eiseman; A P Alvares
Journal:  J Pharmacol Exp Ther       Date:  1980-08       Impact factor: 4.030

8.  Bone marrow transplantation in patients with gold-induced marrow aplasia.

Authors:  J L Baldwin; R Storb; E D Thomas; M Mannik
Journal:  Arthritis Rheum       Date:  1977-06

9.  Auranofin (SK + F 39162) induced enterocolitis in rheumatoid arthritis. A case report.

Authors:  D Jarner; A M Nielsen
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

10.  HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P Perrier; C Raffoux; P Thomas; J N Tamisier; M Busson; A Gaucher; F Streiff
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

View more
  9 in total

Review 1.  Effects of dissolucytotic gold ions on recovering brain lesions.

Authors:  Gorm Danscher; Agnete Larsen
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

2.  Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury.

Authors:  Agnete Larsen; Kristian Kolind; Dan Sonne Pedersen; Peter Doering; Mie Ostergaard Pedersen; Gorm Danscher; Milena Penkowa; Meredin Stoltenberg
Journal:  Histochem Cell Biol       Date:  2008-06-10       Impact factor: 4.304

Review 3.  Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition.

Authors:  Carmelo Scarpignato; Ingvar Bjarnason
Journal:  Curr Gastroenterol Rep       Date:  2019-11-13

Review 4.  Management issues with elderly-onset rheumatoid arthritis: an update.

Authors:  Ignazio Olivieri; Carlo Palazzi; Giovanni Peruz; Angela Padula
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

6.  Effects of gold coating on experimental implant fixation.

Authors:  Kasra Zainali; Gorm Danscher; Thomas Jakobsen; Stig S Jakobsen; Jørgen Baas; Per Møller; Joan E Bechtold; Kjeld Soballe
Journal:  J Biomed Mater Res A       Date:  2009-01       Impact factor: 4.396

Review 7.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 8.  Optimisation of antirheumatic drug treatment in pregnancy.

Authors:  M Ostesen
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

9.  Transient Vasodilation in Mouse 4T1 Tumors after Intragastric and Intravenous Administration of Gold Nanoparticles.

Authors:  Kamil Brzoska; Małgorzata Szczygiel; Agnieszka Drzał; Martyna Sniegocka; Dominika Michalczyk-Wetula; Eva Biela; Martyna Elas; Lucyna Kapka-Skrzypczak; Hanna Lewandowska-Siwkiewicz; Krystyna Urbańska; Marcin Kruszewski
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.